Mankind Pharma may offer investors a better entry point after its listing
Dan Neff
Long-term investors may get a better entry point to invest in the company post-listing.
Synopsis
Business: Unlike its peers, Mankind Pharma started in rural India and is now expanding to urban India. The company earns 97% of its revenues from India. It has also been a uniquely successful player in building branded consumer product portfolios. The company is a market leader in multiple categories – male condoms with its brand Manforce, pregnancy detection kits with PregaNews, and emergency contraceptives with its pill Unwanted-72.
ET Intelligence Group: Delhi-based Mankind Pharma, the fourth largest pharmaceutical company in terms of domestic sales, is coming out with an IPO of ₹4,326 crore that is entirely an offer for sale wherein the private equity investors and promoters are selling a part of their stakes.Business: Unlike its peers, Mankind Pharma started in rural India and is now expanding to urban India. The company earns 97% of its revenues from India. It has also
BY
ET Bureau
4 mins read, Last Updated:
Gift A Story
Share member-only stories with your friends or family and help them read it for free.
Gifting Limit Reached!
Hey , no more stories left for you to gift.
No worries! You will get a limit of 15 stories next month to share with your friends and family.
Gift This Story
Stories Left!
You can gift upto 15 stories in a month.
FONT SIZE
AbcSmall
AbcMedium
AbcLarge
SAVE
PRINT
COMMENT
Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories & personalised newsletters
Login Now
Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions & in-depth stock reports
Subscribe Now
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Read this story for free.
Unlock your 30 days free access to ETPrime now.
Login to unlock
*No card details required.
To read full story, subscribe to ET Prime
Get Unlimited Access to The Economic Times
₹34 per week
Billed annually at ₹2499 ₹1749
Already a Member? Sign In now
Already a Member? Sign In now
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
Rs 49 for 1st month
Then Rs. 1,749 per year
SUBSCRIBE NOW
Valid only with UPI, Credit & Debit Cards Autopay
Choose Payment Mode & Plan
–
–
–
Subscribe Now
(Credit card mandatory)
You can cancel your subscription anytime
–
–
–
Subscribe Now
(Pay Using Netbanking/UPI/Debit Card)
Netbanking, Credit & Debit Card
Subscribe with Google
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial +Includes DocuBay and TimesPrime Membership.
₹399
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial +Includes DocuBay and TimesPrime Membership.
Get ET Prime for just ₹2499 ₹1749/yr
Offer Exclusively For You
Get Flat 30% Off
ON ET PRIME MEMBERSHIP
Avail Offer
Offer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail Offer
Offer Exclusively For You
Get 1 Year Free
With 1 and 2-Year ET prime membership
Avail Offer
Offer Exclusively For You
Get Flat 40% Off
Then ₹ 1749 for 1 year
Avail Offer
Offer Exclusively For You
ET Prime at ₹ 49 for 1 month
Then ₹ 1749 for 1 year
Avail Offer
ETPrime Special Offer
Get 1 Year for Free
with 1-Year Membership
Avail Offer
To Read the full Story, Subscribe to ET Prime
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
Access the exclusive Economic Times stories, Editorial and Expert opinion
Denial of responsibility!TheDailyCheck is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – abuse@thedailycheck.netThe content will be deleted within 24 hours.
